<DOC>
	<DOCNO>NCT02678299</DOCNO>
	<brief_summary>This phase 1/2 open label study assess safety efficacy pixantrone combination bendamsutine , etoposide , CD20 positive B-cell lymphoma , rituximab ( P [ R ] EBEN ) , patient relapse aNHL B- T-cell phenotype .</brief_summary>
	<brief_title>Phase 1/2 Study Combination Pixantrone , Etoposide , Bendamustine , CD20 Positive Tumors , Rituximab Patients With Relapsed Aggressive Non-Hodgkin Lymphomas B- T-cell Phenotype - PREBEN Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients histologically confirm relapse aggressive lymphoma T Bcell phenotype ( include follicular lymphoma grade 3b ) . For excluded histological entity see 'Exclusion criterion ' Phase 1 + Phase 2 'fit ' patient : Age 1870 year time inclusion ECOG PS 01 protocol entry Deemed 'fit ' treat physician Phase 2 'frail ' patient : Age 7185 year time inclusion and/or ECOG PS 23 protocol entry and/or Deemed 'frail ' treat physician At least six month response duration since last give course treatment Estimated life expectancy 3 month longer Measurable disease Hemoglobin ≥ 8 g/dL ( ≥5 mmol/l ) Platelets ≥ 100 x 109/L ; ≥ 75 x 109/L permit bone marrow involvement Absolute neutrophil count ≥ 1.5 x 109/L ; ≥ 1.0 x 109/L permit document bone marrow involvement Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; patient prove Gilbert 's syndrome ( ≤ 5 x ULN ) may enrol . Serum glutamicoxaloacetic transaminase ( AST ) and/or serum glutamicpyruvic transaminase ( ALT ) ≤ 2.5 x ULN , ≤ 5 x ULN elevation due hepatic involvement lymphoma Serum creatinine ≤ 2 x ULNb Women childbearing potential must use safe anticonception ( e.g . contraceptive pill , intrauterine device etc . ) study 12 month last administration study drug Male patient must use contraception duration study 6 month last administration study drug partner childbearing potential Written inform consent Patients primary refractory disease ( e.g . progress platinumcontaining similar salvage therapy ) define &lt; 6 month response duration last give course treatment . Highdose therapy autologous stem cell rescue within last 6 month prior study entry . Following Tcell lymphoma entity : Tcell lymphoblastic lymphoma Hepatosplenic Tcell lymphoma Extranodal NK/T , nasal type Subcutaneous panniculitislike Primary cutaneous Tcell lymphoma Primary leukemic Tcell lymphoma Following Bcell lymphoma entity : Transformed indolent Bcell lymphomas Posttransplant Bcell lymphoproliferative disease HIVassociated Bcell lymphoma Concurrent severe and/or uncontrolled medical disease lymphomarelated Left ventricular ejection fraction ( LVEF ) &lt; 45 % Suspected document central nervous system involvement NHL Patients known antigen positive HIV and/or hepatitis B and/or hepatitis C Patients active , uncontrolled infection Vaccination live , attenuated vaccine within 4 week inclusion Pregnant and/or breastfeed woman History active cancer past 5 year , except basal carcinoma skin stage 0 cervical carcinoma Known hypersensitivity one study drug Unwillingness inability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>